EL7.AI
StocksMedium•30 March 2026•
1 min read

Palisade Bio Reports Positive Phase 1b Results for Crohn's Disease Treatment

Key Facts

1PALI-2108 demonstrated a 47.5% reduction in SES-CD score, indicating significant endoscopic improvement.
240% of patients in the study achieved endoscopic response and remission after two weeks of treatment.
3The company plans to advance PALI-2108 into Phase 2 trials for moderate to severe Crohn's disease.

Palisade Bio (Nasdaq: PALI) announced positive topline results from its Phase 1b study of PALI-2108, an oral PDE4 inhibitor targeting Crohn's disease. The study demonstrated significant clinical activity, with the drug showing a 47.5% reduction in the SES-CD score, a key indicator of endoscopic improvement. Notably, 40% of the participating patients achieved both endoscopic response and remission within just two weeks of treatment. The trial successfully met its primary endpoints for safety and tolerability, providing a strong foundation for further clinical development. Following these favorable results, the company plans to advance PALI-2108 into Phase 2 clinical trials for patients with moderate to severe Crohn's disease. This development marks a significant milestone for the biotech firm as it seeks to address unmet needs in fibrostenotic Crohn's disease.